What Researchers Did
Researchers retrospectively analyzed 205 patients with idiopathic sudden sensorineural hearing loss, comparing outcomes between those treated with prostaglandin E1 plus hyperbaric oxygen therapy and those receiving stellate ganglion block plus hyperbaric oxygen therapy.
What They Found
Overall hearing outcomes were not statistically different between the two groups. However, for patients with initial hearing levels of 80 dB or more, the stellate ganglion block group showed a significantly higher hearing improvement rate of 53.0% compared to 35.3% in the prostaglandin E1 group (p <0.05).
What This Means for Canadian Patients
For Canadian patients experiencing severe idiopathic sudden sensorineural hearing loss, stellate ganglion block combined with hyperbaric oxygen therapy may offer better hearing improvement than prostaglandin E1 with hyperbaric oxygen. Patients should discuss the severity of their hearing loss and available treatment options with their healthcare providers.
Canadian Relevance
This study was conducted outside of Canada and has no direct Canadian connection.
Study Limitations
A key limitation of this study is its retrospective design, which may introduce selection bias.